Aclarion (ACON) Stock
Aclarion Chart
Company Profile
Price: $5.65
Market Cap: $5.74M
Exchange: NASDAQ
CEO: Mr. Brent Ness
Sector: Healthcare
Industry: Medical - Healthcare Information Services
Employees: -0.00B
Headquarters: San Mateo, CA
Website: Aclarion
Business Summary
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.
Aclarion News
Aclarion Announces Northwestern Medicine as First CLARITY Trial Site
Northwestern Medicine is a global leader in clinical trial research, including spine CLARITY is a randomized study designed to demonstrate Nociscan's ability to improve surgical outcomes while reducing costs for chronic low back pain Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc.
Aclarion Announces CLARITY Trial for Nociscan Now Fully Funded
The Company has secured nearly $20 million in gross proceeds in 2025 ensuring complete funding for its pivotal CLARITY trial CLARITY is a prospective, randomized, multicenter study to validate Nociscan's ability to improve surgical outcomes Nociscan aims to become the gold standard in identifying sources of low back pain through MR Spectroscopy (MRS) and Augmented Intelligence (AI) BROOMFIELD, Colo., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that it has secured full funding for its pivotal CLARITY trial which is designed to demonstrate Nociscan's clinical and economic value in spine surgery.
Aclarion to Showcase Groundbreaking NOCISCAN Technology at the Selby Spine Conference
BROOMFIELD, Colo., January 31, 2025 – PRISM MediaWire – Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today its participation in the Selby Spine Conference.
Aclarion to Present at the Virtual Investor Summit Microcap Event on November 21st
BROOMFIELD, CO / ACCESSWIRE / November 14, 2024 / Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq:ACON)(Nasdaq:ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced its participation at the upcoming Virtual Investor Summit Microcap Event on November 21st. The Company will be available for 1-on-1 meetings throughout the day in addition to its formal presentation.
Aclarion to Participate in the 2024 Maxim Healthcare Virtual Summit
Fireside Chat Scheduled for 2:00 PM ET on October 15, 2024 BROOMFIELD, Colo., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that Aclarion's CEO, Brent Ness, has been invited to present at the 2024 Maxim Healthcare Virtual Summit, presented by Maxim Group LLC, on Tuesday, October 15th, 2024, at 2:00 p.m.
Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes
Modic Changes (MC) are MRI Findings Associated With Endplate Damage, Neoinnervation, and Chronic Low Back Pain (cLBP) MR Spectroscopy (MRS) Measurement of Intradiscal Propionic Acid (PA) can Clarify MC Etiology and Help Stratify MC Patients to Potentially Inform Better Treatment Decisions for cLBP Patients Results Presented at the 50th International Society for the Study of the Lumbar Spine (ISSLS) Annual Meeting 2024 BROOMFIELD, CO, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that the Nociscan solution was utilized to better understand Modic changes (MC) in patients suffering from chronic low back pain (cLBP).
Aclarion Added to PRISM Emerging Medical Devices Index
NEW YORK, September 06, 2024 – PRISM MarketView, a leading provider of market insights and company news, is excited to announce that Aclarion, Inc. (NASDAQ: ACON) has been added to the PRISM Emerging Medical Devices Index, which highlights companies at the forefront of innovation and market disruption in the medtech sector.
Aclarion Launches Surgeon Partnership to Apply Nociscan's AI Technology to Personal Injury and Workers Compensation Market
Justin Kubeck, M.D. of Ocean Pain and Spine in Toms River, NJ Will Lead a Statewide Network of Providers That Use Nociscan to Better Serve This Important Segment of Low Back Pain Population
Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan's AI Generated Biomarker Data Changes Surgical Treatment Plans
Surgeons Will Determine Their Surgical Treatment Plan Before Nociscan and Report on How Often the Surgical Plan Changes After Receiving Nociscan Data
Aclarion to Present at August 20th Virtual Investor Summit Microcap Event
BROOMFIELD, CO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that it will be presenting at the upcoming Virtual Investor Summit on August 20th, 2024. Investors may request a one-on-one meeting with management by registering here: https://investorsummitgroup.com .
Aclarion Announces First Commercial Agreement in Michigan
Sheridan Community Hospital is the First Healthcare Institution in Michigan With Nociscan Agreement Expands Nociscan Access to John Keller, MD, a Leading Neurosurgeon and Aclarion Medical Advisor, and the Patients he Serves in Central Michigan BROOMFIELD, CO, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today it has established a commercial agreement with Sheridan Community Hospital in Sheridan, Michigan. The agreement brings Nociscan to central Michigan and leading neurosurgeon, John Keller, MD.
Aclarion Hits Another Key Milestone by Adding Vitality - Third Major Payer to Cover Nociscan in Greater UK
BROOMFIELD, CO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today their third payer coverage of Nociscan by Vitality in London, UK in conjunction with The London Clinic, one of the UK's largest and most renowned independent hospitals. With the addition of coverage by Vitality, payer coverage for Nociscan is now available from three major private medical insurance groups in the UK, a global healthcare market with more than nine million residents.
Aclarion Achieves Milestone With Key Second Payer Coverage of Nociscan by Aviva Throughout Greater London, UK
Aviva is a Top 4 Provider of Private Medical Insurance in the UK By Joining AXA, Approximately 45% of Patients With Private Insurance Now Have Access to Nociscan in the Greater London Spine Care Market BROOMFIELD, CO, July 09, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today an additional key milestone with their second payer coverage of Nociscan by Aviva in London, UK in conjunction with The London Clinic, one of the UK's largest and most renowned independent hospitals. Aviva is a leading provider of private medical insurance in the UK and joins private medical insurance provider, AXA, in covering Nociscan for patients suffering from chronic low back pain.
Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK
AXA is the 2nd Largest Provider of Private Medical Insurance in the UK Payer Coverage is the Most Important Catalyst Aclarion can Achieve to Drive Volume and Revenue AXA Represents the First Insurance Company to Approve Payment for Nociscan BROOMFIELD, CO, June 26, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today their initial payer coverage of Nociscan by AXA in London, UK in conjunction with The London Clinic, one of the UK's largest and most renowned independent hospitals. AXA is a leading provider of private medical insurance in the UK.
Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London
Established in 1932, the London Clinic is the UK's Most Renowned Independent, Private Hospital Payment to Aclarion for Each Nociscan is Being Increased From the Original Contract Contract Extension Aligns Aclarion and The London Clinic With Engaging Payers to Increase Access to Nociscan for Both Patients and Referring Physicians BROOMFIELD, CO, June 25, 2024 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today they are extending their commercial agreement with the prestigious London Clinic in London, UK. The contract extension establishes a higher price point for Nociscan, engages The London Clinic to secure payer coverage decisions from leading private health insurers, and aligns Aclarion with The London Clinic in expanding access to referring physicians throughout the greater London market.
Aclarion Announces Closing of $3.0 Million Public Offering
BROOMFIELD, CO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire - Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced the closing of its public offering of 5,175,000 units, with each unit consisting of one share of common stock (or one pre-funded warrant in lieu thereof), and two common warrants, with each common warrant to purchase one share of common stock. Each unit was sold at a public offering price of $0.58. The common warrants are immediately exercisable at a price of $0.58 per share and expire five years from the date of issuance. The shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants were only purchasable together in this offering, but were issued separately and immediately separable upon issuance.
Aclarion Announces Pricing of $3.0 Million Public Offering
BROOMFIELD, CO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced the pricing of its public offering of 5,175,000 units, with each unit consisting of one share of common stock (or one pre-funded warrant in lieu thereof), and two common warrants, with each common warrant to purchase one share of common stock. Each unit is being sold at a public offering price of $0.58. The common warrants will be immediately exercisable at a price of $0.58 per share and will expire five years from the date of issuance. The shares of common stock (or pre-funded warrants in lieu thereof) and accompanying common warrants can only be purchased together in this offering, but will be issued separately and will be immediately separable upon issuance.
Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership
Company is initiating its pivotal multicenter, prospective, randomized CLARITY trial to build on clinical evidence demonstrating superior surgical outcomes when Nociscan is utilized in surgical decisioning
Why Is Aclarion (ACON) Stock Down 16% Today?
Aclarion (NASDAQ: ACON ) stock is falling on Monday after the healthcare technology company announced additional exchange agreements with accredited investors. According to a filing with the Securities and Exchange Commission (SEC), Aclarion issued 500,000 shares of ACON stock in exchange for $1,185,226 of principal and accrued interest on unsecured non-convertible notes.
Aclarion Earnings
This section highlights Aclarion's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Financial Statements
Access annual & quarterly financial statements for Aclarion, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Revenue | $75.40K | $60.44K | $60.29K | $48.65K | $26.90K |
| Cost of Revenue | $75.73K | $65.30K | $69.17K | $66.25K | $63.18K |
| Gross Profit | $--0.00B | $-4.85K | $-8.88K | $-17.59K | $-36.28K |
| Gross Profit Ratio | -0.43% | -8.03% | -14.73% | -36.16% | -134.90% |
| Research and Development Expenses | $873.34K | $1.09M | $787.85K | $1.05M | $1.74M |
| General and Administrative Expenses | $3.25M | $4.47M | $1.83M | $1.07M | $1.59M |
| Selling and Marketing Expenses | $757.00K | $537.07K | $330.81K | $336.37K | $653.94K |
| Selling General and Administrative Expenses | $4.00M | $5.00M | $2.16M | $1.41M | $2.24M |
| Other Expenses | $- | $-0.00B | $-0.00B | $2.00M | $-0.00B |
| Operating Expenses | $4.88M | $6.09M | $2.94M | $4.46M | $3.98M |
| Cost and Expenses | $4.95M | $6.16M | $3.01M | $4.53M | $4.04M |
| Interest Income | $-0.00B | $2.51K | $474.91K | $-0.00B | $5.00K |
| Interest Expense | $608.29K | $1.51M | $476.48K | $156.06K | $5.00K |
| Depreciation and Amortization | $162.67K | $143.62K | $189.37K | $196.28K | $178.21K |
| EBITDA | $-4.14M | $-5.42M | $-4.28M | $-4.28M | $-3.84M |
| EBITDA Ratio | -5490.97% | -9766.37% | -7723.48% | -8803.14% | -14262.01% |
| Operating Income | $-4.88M | $-6.10M | $-2.95M | $-4.48M | $-4.01M |
| Operating Income Ratio | -6466.48% | -10089.53% | -4897.89% | -9203.03% | -14921.01% |
| Total Other Income Expenses Net | $-35.39K | $-1.51M | $-2.00M | $-157.79K | $-5.96K |
| Income Before Tax | $-4.91M | $-7.61M | $-4.95M | $-4.64M | $-4.02M |
| Income Before Tax Ratio | -6513.41% | -12582.79% | -8210.53% | -9527.35% | -14943.15% |
| Income Tax Expense | $- | $1.51M | $-1.42M | $155.13K | $4.83K |
| Net Income | $-4.91M | $-9.11M | $-3.53M | $-4.79M | $-4.02M |
| Net Income Ratio | -6513.41% | -15074.73% | -5862.46% | -9846.21% | -14961.12% |
| EPS | $-8.82 | $-23.88 | $-62.44 | $-84.63 | $-71.16 |
| EPS Diluted | $-8.82 | $-23.88 | $-62.44 | $-84.63 | $-71.16 |
| Weighted Average Shares Outstanding | 556.81K | 381.60K | 56.60K | 56.60K | 56.55K |
| Weighted Average Shares Outstanding Diluted | 556.81K | 381.60K | 56.60K | 56.60K | 56.55K |
| SEC Filing | Source | Source | Source | Source | Source |
Income Statement Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $14.41K | $10.97K | $10.11K | $13.80K | $19.07K | $17.07K | $25.47K | $22.52K | $18.22K | $10.68K | $9.03K | $11.98K | $10.87K | $25.62K | $11.83K | $9.97K | $22.27K | $8.20K | $8.20K |
| Cost of Revenue | $21.33K | $23.29K | $64.58K | $61.20K | $19.56K | $19.30K | $17.45K | $17.29K | $17.03K | $14.25K | $16.73K | $16.22K | $16.09K | $20.30K | $16.57K | $16.34K | $16.45K | $16.73K | $16.73K |
| Gross Profit | $-6.92K | $-12.32K | $-54.47K | $-47.40K | $--0.00B | $-2.23K | $8.02K | $5.23K | $1.19K | $-3.57K | $-7.71K | $-4.24K | $-5.22K | $5.32K | $-4.74K | $-6.37K | $5.83K | $-8.52K | $-8.52K |
| Gross Profit Ratio | -48.07% | -112.32% | -538.57% | -343.58% | -2.59% | -13.06% | 31.48% | 23.23% | 6.55% | -33.47% | -85.38% | -35.43% | -48.05% | 20.75% | -40.03% | -63.89% | 26.16% | -103.90% | -103.90% |
| Research and Development Expenses | $195.80K | $202.10K | $239.04K | $220.68K | $198.25K | $250.01K | $204.40K | $239.78K | $290.97K | $353.23K | $204.80K | $182.10K | $275.28K | $162.71K | $167.75K | $175.20K | $247.01K | $314.96K | $314.96K |
| General and Administrative Expenses | $860.46K | $696.10K | $845.85K | $721.01K | $770.53K | $1.02M | $807.60K | $908.59K | $1.18M | $1.88M | $491.28K | $760.66K | $438.37K | $404.26K | $222.19K | $208.72K | $198.87K | $331.89K | $331.89K |
| Selling and Marketing Expenses | $232.78K | $225.04K | $181.06K | $179.03K | $192.90K | $129.10K | $177.28K | $183.61K | $159.39K | $124.76K | $69.31K | $121.61K | $78.38K | $64.96K | $65.87K | $63.66K | $112.90K | $192.81K | $192.81K |
| Selling General and Administrative Expenses | $1.09M | $921.14K | $981.79K | $858.26K | $963.43K | $1.15M | $984.88K | $1.09M | $1.34M | $2.01M | $560.59K | $882.27K | $516.75K | $469.23K | $288.06K | $272.38K | $85.97K | $524.70K | $524.70K |
| Other Expenses | $- | $- | $93.00K | $-318.20K | $330.50K | $-11.22K | $--0.00B | $-0.00B | $2.30K | $-1.45K | $--0.00B | $-1.90M | $-2.12M | $-1.58K | $--0.00B | $--0.00B | $- | $- | $- |
| Operating Expenses | $1.29M | $1.12M | $1.22M | $1.08M | $1.16M | $1.40M | $1.19M | $1.33M | $1.63M | $2.36M | $765.39K | $1.06M | $792.03K | $631.94K | $455.81K | $447.58K | $2.33M | $839.79K | $839.79K |
| Cost and Expenses | $1.31M | $1.15M | $1.29M | $1.14M | $1.18M | $1.42M | $1.21M | $1.35M | $1.65M | $2.38M | $782.13K | $1.08M | $808.12K | $652.24K | $472.37K | $463.92K | $2.35M | $856.52K | $856.52K |
| Interest Income | $- | $- | $- | $-0.00B | $- | $47.14K | $1.38K | $-0.00B | $2.07K | $- | $- | $- | $- | $- | $- | $- | $45.03K | $28.81K | $28.81K |
| Interest Expense | $71.53K | $127.85K | $335.82K | $393.44K | $166.33K | $47.14K | $1.38K | $2.07K | $2.07K | $1.34M | $162.74K | $170.50K | $167.63K | $82.83K | $57.21K | $53.41K | $- | $- | $- |
| Depreciation and Amortization | $50.03K | $45.76K | $45.11K | $41.78K | $41.08K | $40.44K | $39.37K | $1.77K | $47.15K | $47.30K | $47.40K | $46.54K | $43.13K | $54.85K | $44.85K | $49.75K | $48.84K | $135.78K | $135.78K |
| EBITDA | $-1.24M | $-1.06M | $-2.02M | $-830.12K | $-790.61K | $-1.38M | $-1.14M | $-788.04K | $-1.60M | $-2.18M | $-738.44K | $-2.92M | $-2.74M | $-578.93K | $-415.79K | $-404.37K | $-2.28M | $-712.40K | $-712.40K |
| EBITDA Ratio | -8639.02% | -9702.57% | -12163.34% | -7860.84% | -4146.87% | -8065.70% | -4637.86% | -5656.65% | -8691.78% | -21726.74% | -8042.81% | -24377.92% | -26363.57% | -2259.69% | -3514.78% | -4055.04% | -10229.48% | -8683.53% | -8683.52% |
| Operating Income | $-1.30M | $-1.14M | $-1.28M | $-1.13M | $-1.16M | $-1.41M | $-1.18M | $-1.33M | $-1.63M | $-2.37M | $-773.10K | $-1.07M | $-797.25K | $-626.62K | $-460.54K | $-453.95K | $-2.33M | $-848.18K | $-848.18K |
| Operating Income Ratio | -8995.34% | -10350.57% | -12609.35% | -8163.66% | -6095.86% | -8236.88% | -4651.90% | -5895.00% | -8963.12% | -22156.25% | -8565.26% | -8922.24% | -7337.83% | -2445.84% | -3893.00% | -4552.26% | -10448.79% | -10338.57% | -10338.57% |
| Total Other Income Expenses Net | $-70.22K | $-102.52K | $-1.12M | $-139.01K | $164.16K | $-58.36K | $-2.20K | $-2.15K | $-0.00B | $-1.34M | $-162.99K | $-2.07M | $-2.16M | $160.78K | $-57.32K | $-53.57K | $-46.32K | $-28.95K | $-28.95K |
| Income Before Tax | $-1.37M | $-1.24M | $-2.40M | $-1.27M | $-998.01K | $-1.46M | $-1.18M | $-1.33M | $-1.63M | $-3.71M | $-936.09K | $-3.14M | $-2.95M | $-465.84K | $-517.86K | $-507.52K | $-2.37M | $-877.12K | $-877.12K |
| Income Before Tax Ratio | -9482.72% | -11285.00% | -23720.61% | -9171.17% | -5234.78% | -8578.71% | -4646.49% | -5901.00% | -8961.88% | -34727.57% | -10371.02% | -26186.90% | -27173.66% | -1818.28% | -4377.51% | -5089.47% | -10656.76% | -10691.43% | -10691.43% |
| Income Tax Expense | $- | $- | $-0.00B | $--0.00B | $496.83K | $35.92K | $3.58K | $1.35K | $--0.00B | $1.34M | $162.99K | $170.50K | $-1.95M | $81.25K | $57.11K | $53.24K | $212.92K | $212.92K | $212.92K |
| Net Income | $-1.37M | $-1.24M | $-2.40M | $-1.27M | $-998.01K | $-1.46M | $-1.19M | $-1.33M | $-1.63M | $-3.71M | $-1.10M | $-3.14M | $-2.95M | $-465.84K | $-517.86K | $-507.52K | $-2.59M | $-1.09M | $-1.09M |
| Net Income Ratio | -9482.72% | -11285.00% | -23720.61% | -9171.17% | -5234.78% | -8578.71% | -4660.53% | -5907.00% | -8960.63% | -34727.57% | -12176.78% | -26186.90% | -27173.66% | -1818.28% | -4377.51% | -5089.47% | -11612.75% | -13286.74% | -13286.74% |
| EPS | $-0.15 | $-0.15 | $-0.44 | $-1.53 | $-1.87 | $-2.83 | $-2.39 | $-2.71 | $-3.34 | $-13.59 | $-19.42 | $-55.41 | $-52.16 | $-8.23 | $-9.15 | $-8.97 | $-45.70 | $-19.26 | $-19.26 |
| EPS Diluted | $-0.15 | $-0.15 | $-0.44 | $-1.53 | $-1.87 | $-2.83 | $-2.39 | $-2.71 | $-3.34 | $-13.59 | $-19.42 | $-55.41 | $-52.16 | $-8.23 | $-9.15 | $-8.97 | $-45.70 | $-19.26 | $-19.26 |
| Weighted Average Shares Outstanding | 9.44M | 8.22M | 5.44M | 825.46K | 532.93K | 517.98K | 496.16K | 490.84K | 488.85K | 272.73K | 56.60K | 56.60K | 56.60K | 56.60K | 56.60K | 56.60K | 56.60K | 56.61K | 56.61K |
| Weighted Average Shares Outstanding Diluted | 9.44M | 8.22M | 5.44M | 825.46K | 532.93K | 517.98K | 496.16K | 490.84K | 488.85K | 272.73K | 56.60K | 56.60K | 56.60K | 56.60K | 56.60K | 56.60K | 56.60K | 56.61K | 56.61K |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.02M | $1.47M | $452.53K | $14.98K | $128.16K |
| Short Term Investments | $- | $- | $- | $- | $- |
| Cash and Short Term Investments | $1.02M | $1.47M | $452.53K | $14.98K | $128.16K |
| Net Receivables | $13.42K | $18.57K | $6.28K | $22.50K | $14.70K |
| Inventory | $- | $301.33K | $-0.00B | $- | $- |
| Other Current Assets | $254.88K | $160.05K | $293.39K | $59.64K | $75.65K |
| Total Current Assets | $1.29M | $1.99M | $732.20K | $97.13K | $218.51K |
| Property Plant Equipment Net | $1.78K | $3.35K | $12.64K | $25.62K | $48.51K |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $1.17M | $1.21M | $1.14M | $1.17M | $1.16M |
| Goodwill and Intangible Assets | $1.17M | $1.21M | $1.14M | $1.17M | $1.16M |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $- | $- | $-1.16M | $-1.19M | $-1.21M |
| Total Non-Current Assets | $1.17M | $1.22M | $1.16M | $1.19M | $1.21M |
| Other Assets | $- | $-0.00B | $- | $- | $- |
| Total Assets | $2.46M | $3.21M | $1.89M | $1.29M | $1.43M |
| Account Payables | $760.53K | $457.56K | $1.06M | $859.53K | $501.03K |
| Short Term Debt | $1.13M | $- | $2.00M | $2.38M | $515.55K |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $-4.64K | $- | $3.14M | $- |
| Other Current Liabilities | $1.30M | $231.11K | $4.56M | $5.14M | $2.12M |
| Total Current Liabilities | $3.19M | $1.42M | $7.62M | $8.38M | $3.13M |
| Long Term Debt | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $- | $457.56K | $- | $--0.00B | $--0.00B |
| Other Liabilities | $- | $-457.56K | $- | $- | $- |
| Total Liabilities | $3.19M | $1.42M | $7.62M | $8.38M | $3.13M |
| Preferred Stock | $- | $- | $-0.00B | $-0.00B | $-0.00B |
| Common Stock | $-0.00B | $-0.00B | $-0.00B | $-0.00B | $-0.00B |
| Retained Earnings | $-44.28M | $-39.91M | $-31.89M | $-25.93M | $-20.44M |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $- | $-0.00B |
| Other Total Stockholders Equity | $43.55M | $41.60M | $26.16M | $18.85M | $18.74M |
| Total Stockholders Equity | $-728.00K | $1.79M | $-5.73M | $-7.08M | $-1.70M |
| Total Equity | $-728.00K | $1.79M | $-5.73M | $-7.08M | $-1.70M |
| Total Liabilities and Stockholders Equity | $2.46M | $3.21M | $1.89M | $1.29M | $1.43M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $2.46M | $3.21M | $1.89M | $1.29M | $1.43M |
| Total Investments | $- | $- | $- | $- | $- |
| Total Debt | $1.13M | $4.64K | $2.00M | $2.38M | $515.55K |
| Net Debt | $104.66K | $-1.47M | $1.55M | $2.36M | $387.39K |
Balance Sheet Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $1.31M | $1.17M | $2.14M | $1.03M | $161.45K | $604.52K | $447.98K | $1.47M | $2.66M | $3.79M | $50.45K | $452.53K | $1.30M | $2.09M | $-14.98K | $14.98K | $-128.16K |
| Short Term Investments | $- | $50.00K | $50.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $29.97K | $- | $256.33K |
| Cash and Short Term Investments | $1.31M | $1.17M | $2.14M | $1.03M | $161.45K | $604.52K | $447.98K | $1.47M | $2.66M | $3.79M | $50.45K | $452.53K | $1.30M | $2.09M | $14.98K | $14.98K | $128.16K |
| Net Receivables | $16.95K | $19.71K | $17.37K | $13.42K | $21.19K | $10.37K | $17.15K | $18.57K | $25.50K | $5.04K | $12.52K | $6.28K | $10.68K | $10.58K | $- | $22.50K | $- |
| Inventory | $- | $- | $-0.00B | $-0.00B | $10.00K | $10.00K | $10.00K | $301.33K | $-0.00B | $10.00K | $- | $-0.00B | $- | $-0.00B | $- | $- | $- |
| Other Current Assets | $568.27K | $659.36K | $428.31K | $254.88K | $354.62K | $346.41K | $410.81K | $160.05K | $198.31K | $591.45K | $502.51K | $293.39K | $155.34K | $614.58K | $- | $59.64K | $- |
| Total Current Assets | $1.90M | $1.85M | $2.54M | $1.19M | $364.95K | $798.09K | $675.53K | $1.99M | $2.88M | $4.39M | $565.48K | $732.20K | $1.47M | $2.72M | $14.98K | $97.13K | $128.16K |
| Property Plant Equipment Net | $-0.00B | $1.19K | $1.49K | $1.78K | $2.06K | $2.34K | $2.84K | $3.35K | $4.04K | $6.63K | $10.92K | $12.64K | $15.05K | $17.87K | $- | $25.62K | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $1.29M | $1.24M | $1.19M | $1.17M | $1.18M | $1.20M | $1.18M | $1.21M | $1.22M | $1.22M | $1.23M | $1.14M | $1.17M | $1.21M | $- | $1.17M | $- |
| Goodwill and Intangible Assets | $1.29M | $1.24M | $1.19M | $1.17M | $1.18M | $1.20M | $1.18M | $1.21M | $1.22M | $1.22M | $1.23M | $1.14M | $1.17M | $1.21M | $- | $1.17M | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $- | $- | $- | $100.59K | $- | $--0.00B | $-1.19M | $- | $-1.22M | $- | $- | $- | $-0.00B | $782.61K | $-14.98K | $- | $-128.16K |
| Total Non-Current Assets | $1.29M | $1.24M | $1.19M | $1.27M | $1.18M | $1.21M | $1.19M | $1.22M | $1.22M | $1.23M | $1.24M | $1.16M | $1.19M | $2.01M | $-14.98K | $1.19M | $-128.16K |
| Other Assets | $- | $- | $- | $-0.00B | $- | $-0.00B | $- | $-0.00B | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $3.19M | $3.09M | $3.73M | $2.46M | $1.54M | $2.00M | $1.86M | $3.21M | $4.10M | $5.62M | $1.81M | $1.89M | $2.65M | $4.72M | $- | $1.29M | $- |
| Account Payables | $331.76K | $179.12K | $195.71K | $760.53K | $686.20K | $607.62K | $544.74K | $457.56K | $718.28K | $1.18M | $1.39M | $1.06M | $1.02M | $939.27K | $- | $859.53K | $- |
| Short Term Debt | $- | $777.09K | $670.15K | $1.13M | $727.54K | $118.84K | $- | $- | $- | $- | $2.00M | $2.00M | $2.00M | $-1.13M | $- | $2.38M | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $379.12K | $513.00K | $- | $-4.64K | $- | $- | $- | $- | $3.92M | $3.28M | $- | $3.14M | $- |
| Other Current Liabilities | $346.50K | $490.43K | $355.95K | $1.30M | $957.47K | $1.27M | $191.66K | $231.11K | $450.15K | $197.04K | $5.35M | $4.56M | $9.12M | $374.58K | $- | $5.14M | $- |
| Total Current Liabilities | $678.27K | $1.45M | $1.22M | $3.19M | $2.37M | $1.99M | $736.41K | $1.42M | $1.17M | $1.38M | $8.74M | $7.62M | $12.14M | $11.87M | $- | $8.38M | $- |
| Long Term Debt | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $- | $- | $- | $- | $- | $-0.00B | $- | $457.56K | $718.28K | $- | $3.39M | $3.06M | $--0.00B | $- | $- | $--0.00B | $- |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $-457.56K | $-718.28K | $- | $-3.39M | $-3.06M | $- | $- | $- | $- | $- |
| Total Liabilities | $678.27K | $1.45M | $1.22M | $3.19M | $2.37M | $1.99M | $736.41K | $1.42M | $1.17M | $1.38M | $8.74M | $7.62M | $12.14M | $11.87M | $- | $8.38M | $- |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $-0.00B | $- | $-0.00B | $- | $-0.00B | $-0.00B | $-0.00B | $-0.00B | $-0.00B | $-0.00B | $-0.00B |
| Common Stock | $-0.00B | $-0.00B | $-0.00B | $-0.00B | $-0.00B | $-0.00B | $-0.00B | $-0.00B | $-0.00B | $-0.00B | $-0.00B | $-0.00B | $-0.00B | $-0.00B | $- | $-0.00B | $- |
| Retained Earnings | $-49.27M | $-47.92M | $-46.68M | $-44.28M | $-43.02M | $-42.02M | $-40.55M | $-39.91M | $-38.58M | $-36.95M | $-33.11M | $-31.89M | $-28.46M | $-26.04M | $- | $-25.93M | $- |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $- | $- | $- | $-0.00B | $- | $-0.00B | $- | $- | $- | $--0.00B | $--0.00B | $-7.08M | $- | $-1.70M |
| Other Total Stockholders Equity | $51.78M | $49.56M | $49.19M | $43.55M | $42.19M | $42.03M | $41.68M | $41.60M | $41.51M | $41.18M | $26.18M | $26.16M | $18.97M | $18.89M | $- | $18.85M | $- |
| Total Stockholders Equity | $2.51M | $1.64M | $2.51M | $-728.00K | $-827.98K | $10.22K | $1.13M | $1.79M | $2.93M | $4.24M | $-6.93M | $-5.73M | $-9.49M | $-7.15M | $-7.08M | $-7.08M | $-1.70M |
| Total Equity | $2.51M | $1.64M | $2.51M | $-728.00K | $-827.98K | $10.22K | $1.13M | $1.79M | $2.93M | $4.24M | $-6.93M | $-5.73M | $-9.49M | $-7.15M | $-7.08M | $-7.08M | $-1.70M |
| Total Liabilities and Stockholders Equity | $3.19M | $3.09M | $3.73M | $2.46M | $1.54M | $2.00M | $1.86M | $3.21M | $4.10M | $5.62M | $1.81M | $1.89M | $2.65M | $4.72M | $-7.08M | $1.29M | $-1.70M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $3.19M | $3.09M | $3.73M | $2.46M | $1.54M | $2.00M | $1.86M | $3.21M | $4.10M | $5.62M | $1.81M | $1.89M | $2.65M | $4.72M | $-7.08M | $1.29M | $-1.70M |
| Total Investments | $- | $50.00K | $50.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $29.97K | $- | $256.33K |
| Total Debt | $- | $777.09K | $670.15K | $1.13M | $727.54K | $118.84K | $- | $4.64K | $- | $- | $2.00M | $2.00M | $2.00M | $7.28M | $- | $2.38M | $- |
| Net Debt | $-1.31M | $-395.60K | $-1.47M | $94.66K | $566.09K | $-485.68K | $-447.98K | $-1.47M | $-2.66M | $-3.79M | $1.95M | $1.55M | $698.19K | $5.19M | $14.98K | $2.36M | $128.16K |
Annual Cash Flow
| Breakdown | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 | December 31, 2019 |
|---|---|---|---|---|---|
| Net Income | $-4.91M | $-7.61M | $-4.95M | $-4.64M | $-4.02M |
| Depreciation and Amortization | $162.67K | $193.62K | $189.37K | $196.28K | $178.21K |
| Deferred Income Tax | $- | $- | $-343.12K | $- | $-649.11K |
| Stock Based Compensation | $456.00K | $1.29M | $177.49K | $26.13K | $28.04K |
| Change in Working Capital | $622.87K | $805.30K | $676.29K | $538.27K | $-358.23K |
| Accounts Receivables | $-1.49K | $-12.29K | $16.22K | $-7.81K | $-14.70K |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $220.63K | $-603.10K | $199.60K | $342.23K | $-249.96K |
| Other Working Capital | $403.73K | $1.42M | $460.46K | $203.85K | $-93.58K |
| Other Non Cash Items | $22.88K | $3.79K | $1.90M | $79.12K | $649.11K |
| Net Cash Provided by Operating Activities | $-3.65M | $-5.31M | $-2.35M | $-3.80M | $-4.17M |
| Investments in Property Plant and Equipment | $- | $-208.87K | $-152.00K | $-179.03K | $-267.21K |
| Acquisitions Net | $- | $1.00K | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- |
| Other Investing Activities | $-119.52K | $1.00K | $-102.00K | $-174.28K | $-244.86K |
| Net Cash Used for Investing Activities | $-119.52K | $-207.87K | $-152.00K | $-179.03K | $-267.21K |
| Debt Repayment | $2.25M | $- | $2.94M | $- | $515.55K |
| Common Stock Issued | $1.46M | $8.55M | $- | $- | $1.80K |
| Common Stock Repurchased | $-1.00K | $- | $- | $- | $- |
| Dividends Paid | $- | $-415.52K | $- | $- | $- |
| Other Financing Activities | $-398.22K | $6.60M | $- | $3.86M | $4.87M |
| Net Cash Used Provided by Financing Activities | $3.31M | $6.55M | $2.94M | $3.86M | $2.95M |
| Effect of Forex Changes on Cash | $- | $--0.00B | $- | $- | $- |
| Net Change in Cash | $-451.74K | $1.03M | $437.55K | $-113.18K | $-1.49M |
| Cash at End of Period | $1.03M | $1.48M | $452.53K | $14.98K | $128.16K |
| Cash at Beginning of Period | $1.48M | $452.53K | $14.98K | $128.16K | $1.62M |
| Operating Cash Flow | $-3.65M | $-5.31M | $-2.35M | $-3.80M | $-4.17M |
| Capital Expenditure | $-119.52K | $-208.87K | $-152.00K | $-179.03K | $-267.21K |
| Free Cash Flow | $-3.77M | $-5.52M | $-2.50M | $-3.97M | $-4.44M |
Cash Flow Charts
| Breakdown | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-1.37M | $-1.24M | $-2.40M | $-1.27M | $-998.01K | $-1.46M | $-1.18M | $-1.33M | $-1.63M | $-3.71M | $-936.09K | $-3.14M | $-830.18K | $-465.84K | $-517.86K | $-507.52K | $-2.37M | $-877.12K | $-877.12K |
| Depreciation and Amortization | $50.03K | $45.76K | $45.11K | $41.78K | $41.08K | $40.44K | $39.37K | $51.77K | $47.15K | $47.30K | $47.40K | $46.54K | $48.71K | $49.27K | $44.85K | $49.75K | $-125.02K | $135.78K | $135.78K |
| Deferred Income Tax | $- | $- | $- | $-162.32K | $-330.25K | $11.80K | $-83.96K | $- | $- | $- | $- | $-46.54K | $-124.01K | $-247.81K | $- | $- | $- | $- | $- |
| Stock Based Compensation | $74.71K | $70.30K | $85.83K | $99.53K | $137.31K | $136.63K | $82.53K | $237.83K | $326.20K | $701.50K | $23.12K | $84.01K | $84.01K | $4.73K | $4.73K | $6.53K | $6.53K | $6.53K | $6.53K |
| Change in Working Capital | $117.68K | $-63.22K | $-1.19M | $254.03K | $35.12K | $285.28K | $48.45K | $-95.75K | $159.68K | $135.24K | $606.13K | $532.43K | $-215.01K | $144.21K | $214.66K | $357.31K | $23.68K | $-0.00B | $-0.00B |
| Accounts Receivables | $2.76K | $-2.50K | $-2.62K | $7.92K | $-10.82K | $--0.00B | $1.42K | $6.93K | $-20.46K | $7.48K | $-6.24K | $4.40K | $--0.00B | $20.53K | $-8.62K | $5.43K | $-6.35K | $-3.44K | $-3.45K |
| Inventory | $- | $- | $- | $--0.00B | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $97.64K | $68.32K | $-640.16K | $12.86K | $149.86K | $-24.63K | $82.54K | $-256.08K | $-466.10K | $-712.42K | $831.49K | $41.77K | $79.61K | $-94.07K | $172.29K | $186.38K | $- | $- | $- |
| Other Working Capital | $17.28K | $-129.04K | $-543.94K | $233.25K | $-103.91K | $309.91K | $-83.96K | $153.40K | $646.24K | $-688.84K | $-219.12K | $486.26K | $-294.53K | $217.75K | $50.98K | $165.50K | $30.03K | $4.16K | $4.16K |
| Other Non Cash Items | $68.11K | $130.70K | $1.89M | $287.83K | $162.25K | $42.87K | $83.96K | $-0.00B | $1.90K | $1.09M | $-707.32K | $1.95M | $--0.00B | $23.24K | $7.16K | $7.88K | $-86.84K | $156.97K | $156.97K |
| Net Cash Provided by Operating Activities | $-1.06M | $-1.05M | $-2.38M | $-744.50K | $-952.51K | $-947.54K | $-1.01M | $-1.14M | $-1.10M | $-2.82M | $-259.43K | $-574.79K | $-1.04M | $-492.20K | $-246.47K | $-86.05K | $-2.56M | $-577.13K | $-577.13K |
| Investments in Property Plant and Equipment | $- | $- | $-63.66K | $-33.92K | $-12.97K | $-60.91K | $-11.72K | $-48.25K | $-38.66K | $10.70K | $-132.65K | $-17.02K | $-60.16K | $-51.20K | $-23.63K | $-33.75K | $-0.00B | $-2.37K | $-2.37K |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $-103.70K | $-93.87K | $-63.66K | $-33.92K | $-12.97K | $-60.91K | $-11.72K | $-48.25K | $-38.66K | $-38.30K | $-82.65K | $-17.02K | $-10.16K | $-51.20K | $-23.63K | $-32.90K | $-28.77K | $-56.31K | $-56.31K |
| Net Cash Used for Investing Activities | $-103.70K | $-93.87K | $-63.66K | $-33.92K | $-12.97K | $-60.91K | $-11.72K | $-48.25K | $-38.66K | $11.70K | $-132.65K | $-17.02K | $-60.16K | $-51.20K | $-23.63K | $-33.75K | $-27.91K | $-58.68K | $-58.68K |
| Debt Repayment | $- | $-0.00B | $- | $250.00K | $750.00K | $1.25M | $- | $- | $- | $- | $- | $-257.47K | $- | $- | $319.00K | $30.18K | $- | $- | $- |
| Common Stock Issued | $529.25K | $304.50K | $4.14M | $1.46M | $- | $- | $1.00K | $- | $- | $8.55M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $-1.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-287.31K | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $769.50K | $-116.04K | $-727.14K | $1.38M | $-227.59K | $-85.00K | $- | $-365.06K | $- | $-2.00M | $287.31K | $- | $247.28K | $2.57M | $- | $- | $2.64M | $597.53K | $597.53K |
| Net Cash Used Provided by Financing Activities | $1.30M | $188.46K | $3.56M | $1.63M | $522.41K | $1.17M | $- | $-365.06K | $- | $6.55M | $-287.31K | $-257.47K | $307.47K | $2.57M | $319.00K | $30.18K | $2.64M | $597.53K | $597.53K |
| Effect of Forex Changes on Cash | $- | $- | $- | $1.00K | $-0.00B | $--0.00B | $--0.00B | $365.06K | $- | $- | $287.31K | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $139.41K | $-959.95K | $1.11M | $859.62K | $-443.07K | $156.54K | $-1.02M | $-1.18M | $-1.14M | $3.74M | $-392.08K | $-849.28K | $-789.18K | $2.03M | $48.91K | $-89.63K | $53.02K | $-38.28K | $-38.28K |
| Cash at End of Period | $1.32M | $1.18M | $2.14M | $1.03M | $171.45K | $614.52K | $457.98K | $1.48M | $2.67M | $3.80M | $60.45K | $452.53K | $1.30M | $2.09M | $63.89K | $14.98K | $104.61K | $51.59K | $-38.28K |
| Cash at Beginning of Period | $1.18M | $2.14M | $1.03M | $171.45K | $614.52K | $457.98K | $1.48M | $2.67M | $3.80M | $60.45K | $452.53K | $1.30M | $2.09M | $63.89K | $14.98K | $104.61K | $51.59K | $89.88K | $- |
| Operating Cash Flow | $-1.06M | $-1.17M | $-2.38M | $-744.50K | $-952.51K | $-947.54K | $-1.01M | $-1.14M | $-1.10M | $-2.82M | $-259.43K | $-574.79K | $-1.04M | $-492.20K | $-246.47K | $-86.05K | $-2.56M | $-577.13K | $-577.13K |
| Capital Expenditure | $-103.70K | $- | $-63.66K | $-33.92K | $-12.97K | $-60.91K | $-11.72K | $-48.25K | $-38.66K | $10.70K | $-132.65K | $-17.02K | $-60.16K | $-51.20K | $-23.63K | $-33.75K | $-0.00B | $-2.37K | $-2.37K |
| Free Cash Flow | $-1.16M | $-1.15M | $-2.45M | $-778.41K | $-965.48K | $-1.01M | $-1.02M | $-1.18M | $-1.14M | $-2.81M | $-392.08K | $-591.81K | $-1.10M | $-543.40K | $-270.09K | $-119.81K | $-2.55M | $-579.50K | $-579.50K |
Aclarion Stock Forecast
Analyst ratings, price targets, and earnings estimates for ACON.
ACON Analyst Ratings
Strong Buy
Based on 1 analysts in the past 3 months
Recent Price Targets
Recommendation Trends
Analyst Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Revenue Estimates
Net Income Estimates
EPS Estimates
Latest Price Target Updates
| Date | Analyst | Firm | Price Target | Price When Posted | Upside |
|---|
Aclarion Dividends
Explore Aclarion's dividend history, including dividend yield, payout ratio, and historical payments.
Peers: Medical - Healthcare Information Services
This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.
| Company | Market Cap | Price | EPS | P/E Ratio | P/B Ratio |
|---|---|---|---|---|---|
|
$- | $ | $ | $ | $ |
EUDA Health Holdings Limited
EUDA
|
$159.39M | $4.29 | $-0.37 | $-3.88 | $-5.20 |
FOXO Technologies Inc.
FOXO
|
$5.09M | $0.22 | $-6.27 | $-0.05 | $-0.10 |
Augmedix, Inc.
AUGX
|
$115.91M | $2.35 | $-0.44 | $-13.41 | $11.02 |
ETAO International Co., Ltd.
ETAO
|
$9.78M | $1.91 | $-169.64 | $-1.19 | $-68.65 |
Akili, Inc.
AKLI
|
$34.10M | $0.43 | $-0.76 | $-0.64 | $0.65 |
Healthcare Triangle, Inc.
HCTI
|
$3.46M | $0.61 | $-2.92 | $-0.94 | $21.62 |
Mangoceuticals, Inc.
MGRX
|
$10.22M | $4.11 | $-6.45 | $-0.64 | $7.65 |
HealthStream, Inc.
HSTM
|
$1.01B | $33.13 | $0.50 | $54.32 | $2.43 |
National Research Corporation
NRC
|
$391.81M | $16.69 | $1.26 | $31.35 | $19.83 |
Forian Inc.
FORA
|
$75.68M | $2.44 | $0.35 | $8.45 | $3.58 |
Related Metrics
Explore detailed financial metrics and analysis for ACON.